FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer

INTRODUCTION: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced non-small-cell lung cancer (NSCLC) selected by tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression. METHODS: Patients with PD-L1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Thorac Oncol
Autors principals: Spigel, David R., Chaft, Jamie E., Gettinger, Scott, Chao, Bo H., Dirix, Luc, Schmid, Peter, Chow, Laura Q. M., Hicks, Rodney J., Leon, Larry, Fredrickson, Jill, Kowanetz, Marcin, Sandler, Alan, Funke, Roel, Rizvi, Naiyer A.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7455890/
https://ncbi.nlm.nih.gov/pubmed/29775807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.05.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars